Cargando…
Inhibition of the Myocardin-Related Transcription Factor Pathway Increases Efficacy of Trametinib in NRAS-Mutant Melanoma Cell Lines
SIMPLE SUMMARY: Malignant melanoma is the most aggressive skin cancer, and treatment is often ineffective due to the development of resistance to targeted therapeutic agents. The most prevalent form of melanoma with a mutated BRAF gene has an effective treatment, but the second most common mutation...
Autores principales: | Appleton, Kathryn M., Palsuledesai, Charuta C., Misek, Sean A., Blake, Maja, Zagorski, Joseph, Gallo, Kathleen A., Dexheimer, Thomas S., Neubig, Richard R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122681/ https://www.ncbi.nlm.nih.gov/pubmed/33921974 http://dx.doi.org/10.3390/cancers13092012 |
Ejemplares similares
-
Rho-mediated signaling promotes BRAF inhibitor resistance in de-differentiated melanoma cells
por: Misek, SA, et al.
Publicado: (2019) -
BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib
por: Ranzani, Marco, et al.
Publicado: (2015) -
NRAS mutant melanoma – undrugable?
por: Posch, Christian, et al.
Publicado: (2013) -
Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer
por: Vujic, Igor, et al.
Publicado: (2014) -
The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRAS(Q61K) melanoma
por: Simbulan-Rosenthal, Cynthia M., et al.
Publicado: (2017)